Randomized trial · people
Semaglutide (oral): fewer major heart events than placebo in SOUL
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with type 2 diabetes and heart or kidney disease, this large trial found daily oral semaglutide lowered the risk of major heart events compared with placebo, with no rise in serious side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 9650
- Published
- 2025
- Journal
- N Engl J Med
What they tested
The team tested whether daily oral semaglutide lowers the risk of heart attack, stroke and heart-related death in people with type 2 diabetes who also have artery disease, kidney disease or both.
How the study was done
A randomized, double-blind, placebo-controlled trial in 9650 adults aged 50 or older with type 2 diabetes and known atherosclerotic cardiovascular disease (artery disease from plaque buildup), chronic kidney disease or both. They took oral semaglutide once a day by mouth (top dose 14 mg) or placebo, a dummy pill, on top of their usual care, and were followed for a median of 49.5 months.

Model. Individual results vary.
What they found
A major heart event (heart-related death, a nonfatal heart attack or a nonfatal stroke) happened in 579 of 4825 people on oral semaglutide (12.0%) and 668 of 4825 on placebo (13.8%). Put as rates, that was 3.1 events per 100 person-years with the drug against 3.7 with placebo. The hazard ratio, a measure of relative risk over time, came to 0.86, with a 95% confidence range from 0.77 up to 0.96 and a P value of 0.006. The key secondary outcomes, including a combined measure of major kidney disease events, showed no significant gap between groups, and serious adverse events were 47.9% with oral semaglutide versus 50.3% with placebo, with gastrointestinal disorders at 5.0% and 4.4%.
What it doesn’t show
The trial only included people aged 50 or older with type 2 diabetes plus artery or kidney disease, so it does not show the same effect in people without diabetes or at lower risk, and it found no significant kidney benefit. It was funded by Novo Nordisk.
The paper
McGuire et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025.
The compounds
More studies on Semaglutide (oral)
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1Randomized trial · people · 2023
- Semaglutide (oral): heart risk not higher than placebo in PIONEER 6Randomized trial · people · 2019
- Every study on Semaglutide (oral)
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.